Customised, individualised treatment of metastatic non-small-cell lung carcinoma (NSCLC)

Muhammad Furrukh*, Mansour Al-Moundhri, Khawaja F. Zahid, Shiyam Kumar, Ikram Burney

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)


A series of phase II and randomised phase III trials in Asia and Europe have confirmed recently that advanced stage non-small-cell lung carcinoma patients with adenocarcinoma subtypes harbouring specific mutations when subjected to targeted therapy experience equivalent survival outcomes as those treated with chemotherapy and are spared from its side effects. The concept of chemotherapy for all is fading, and therapy optimisation has emerged as a paradigm shift in treatment. This article briefly describes cellular mechanisms involved in lung carcinogenesis which provide a molecular basis for targeted therapy. Advances in molecular biology have improved our understanding of mechanisms involved in primary or secondary drug resistance. Evolving biomarkers of prognostic and predictive importance, and the impact of translational research on outcomes are also covered. A marker is considered prognostic if it predicts the outcome, regardless of the treatment, and predictive if it predicts the outcome of a specific therapy.

Original languageEnglish
Pages (from-to)202-217
Number of pages16
JournalSultan Qaboos University Medical Journal
Issue number2
Publication statusPublished - May 2013


  • Bevacizumab
  • Biological markers
  • Carcinoma
  • Epidermal growth factor
  • Erlotinib
  • Lung neoplasm
  • Non-small-cell lung
  • Protein kinase inhibitors
  • Receptor
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Customised, individualised treatment of metastatic non-small-cell lung carcinoma (NSCLC)'. Together they form a unique fingerprint.

Cite this